Biocytogen
- Company typePublic
- Founded2008
- HeadquartersDaxing, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
Biocytogen firmographics
Firmographics- Name
- Biocytogen
- Legal name
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Website
- https://biocytogen.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Biocytogen industry classification
Industry- Product category
- Antibody Drug Discovery and Preclinical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Biocytogen is headquartered
LocationHeadquarters
- HQ city
- Daxing
- HQ country
- China
- HQ region
- Asia
Offices7 records
Markets served
Biocytogen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Platform Licensing: Licensing of proprietary RenMice platforms (RenMab, RenLite, RenNano, RenTCR) to pharmaceutical and biotech partners for internal R&D programs. Partners gain access to fully human antibody discovery capabilities in exchange for licensing fees.
- Milestone Payments: Development and regulatory milestone payments triggered by partner achievements such as IND clearances, clinical trial phases, and approvals. Example: $5M milestone payment from IDEAYA for first patient dosed in Phase 1 trial.
- Royalty on Product Sales: Ongoing royalty payments based on future product sales from therapeutics developed using licensed platforms.
- Preclinical Services: Fee-for-service preclinical pharmacology, gene-editing, and animal model services provided to pharmaceutical and biotech clients.
- Animal Model Sales: Sale of off-the-shelf and custom genetically modified mouse models under the BioMice brand.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Biocytogen product offering
Product offeringCore offering
Biocytogen provides integrated antibody drug discovery solutions combining proprietary RenMice humanized mouse platforms (RenMab, RenLite, RenNano, RenTCR mimic), the AI-powered RenSuper Workstation, a 1M+ fully human antibody library, BioMice animal models, and preclinical pharmacology and gene editing services for global pharmaceutical and biotechnology clients.
Product overview
Biocytogen offers a comprehensive integrated platform for antibody-based drug discovery spanning from target identification to IND submission. The core offering includes proprietary RenMice platforms (RenMab® for monoclonal antibodies, RenLite® for bispecific antibodies, RenNano® for heavy-chain-only antibodies, RenTCR mimic™ for TCR discovery) combined with the AI-powered RenSuper™ Workstation for accelerated antibody discovery. The company provides a 1M+ fully human antibody library covering 1,000+ targets, supported by extensive preclinical services including gene editing, animal models (BioMice™), pharmacology studies, and AAALAC-accredited animal facility services. The platform enables generation of diverse antibody modalities including bispecific antibodies, ADCs, VHHs, and TCR mimic antibodies for global pharmaceutical and biotechnology partners.
Differentiator
Problem solved
Functional benefit
Brands
- BioMice: Sub-brand for off-the-shelf animal and cell models, including humanized mouse models and custom gene-edited models for preclinical research.
- RenSuper Biologics
- RenMice
- RenMice HiTS Platform
Products and services
- RenMab Platform Fully human monoclonal antibody discovery platform using mice with complete replacement of murine variable regions by full human heavy and kappa light chain V(D)J loci in situ; produces higher antibody diversity with normal immune system function comparable to wild-type mice, for pharmaceutical and biotechnology antibody discovery programs.
- RenLite Platform Bispecific and multispecific antibody discovery platform replacing murine heavy chain variable regions with human ones while using only one common kappa light chain, eliminating chain mispairing and enabling efficient assembly of bispecific antibodies and bispecific ADCs for partners developing multispecific therapeutics.
- RenNano Platform Fully human heavy chain-only antibody (HCAb) and VHH discovery platform containing complete human heavy chain variable genes with modified mouse constant regions, generating HCAbs with nM-level binding affinity independent of light chains, ideal for bispecific/multispecific antibodies, ADCs and CAR cell therapies.
- RenTCR mimic Platform TCR mimic antibody discovery platform modified to express human leukocyte antigen (HLA) genes, enabling high-throughput screening of antibodies with high specificity and affinity against intracellular tumor antigens that are inaccessible to conventional antibody approaches.
- RenSuper Workstation AI-powered antibody discovery platform providing off-the-shelf access to an experimentally validated library of fully human therapeutic antibody sequences paired with a fully automated high-throughput antibody manufacturing automation center, designed to accelerate antibody identification, validation and production for pharmaceutical and biotechnology partners.
- BioMice Animal Models Off-the-shelf and custom genetically engineered animal models including humanized immune checkpoint mouse models, immunodeficient rodent models, knockout models, disease-specific models, and engineered cell lines, used by researchers for preclinical drug evaluation, target validation and mechanistic studies.
- Preclinical Pharmacology Services Comprehensive in vivo, ex vivo, and in vitro pharmacology capabilities including drug efficacy evaluation, pharmacodynamic (PD) and pharmacokinetic (PK) studies, biomarker response assessment, and non-GLP toxicity studies for pharmaceutical and biotechnology clients progressing drug candidates toward IND filing.
- Gene Editing Services Custom gene editing services including conventional knockout/knockin, conditional knockout/knockin, point mutation knockin, Rosa26 locus knockin, tag/reporter genes, and Tol2 transgenic mouse models, using Biocytogen's proprietary gene editing technologies for academic, biotech and pharmaceutical researchers.
- Fully Human Antibody Library (1M+ sequences) Library of over 1 million fully human antibody sequences against more than 1,000 targets, including 30+ dual-TAA targeting bispecific ADCs, 200+ tumor-associated antigen projects, 30+ autoimmune projects, 10+ TCR mimic projects, and 1,500+ VHH antibody projects, offered to partners for in-licensing and co-development.
- RenMice HiTS Platform Open collaborative antibody hit discovery project using RenMab mice with targeted genetic disruption to generate antibody hits against thousands of potential drug targets in partnership with global pharmaceutical and biotechnology collaborators.
- Animal Center Services AAALAC-accredited animal facility services including breeding and colony management, cryopreservation, rederivation, microbial detection, and operational consulting for laboratory animal facilities, available to academic and industry researchers.
Quantifiable outcome
- 350+ therapeutic antibody agreements established globally as of December 2025
- +2 more outcomes
Companies that use Biocytogen
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Biocytogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Biocytogen partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major and standard.
- Sihuan Pharmaceutical Holdings GroupmajorStrategic partnership to develop innovative antibody-based therapeutics across multiple disease areas including weight loss treatments. Biocytogen contributes its fully human antibody discovery platform including target-humanized mouse models and AI-driven antibody discovery, while Sihuan provides drug development, manufacturing, and commercialization capabilities. Collaboration aims to advance molecules including bispecific antibodies, ADCs, VHHs, and TCR-based therapeutics.
- Taisho Pharmaceutical Co., Ltd.standardPlatform license agreement granting Taisho access to Biocytogen's proprietary RenNano fully human heavy chain-only antibody discovery platform for Taisho's internal R&D programs. Taisho will use RenNano mice to enable generation and screening of fully human HCAbs in vivo for next-generation VHH-based antibody modalities including bispecific antibodies, ADCs, and in vivo CAR-T therapies.
- NEOK Bio, Inc.majorPartnership for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate for solid tumors. Biocytogen developed the bispecific antibody platform licensed to NEOK Bio in 2024. FDA IND clearance received March 2026 with Phase 1 trial planned for Q2 2026. Initial data expected in 2027.
- Moonlight Bio, Inc.majorStrategic collaboration to develop cutting-edge cell therapies for difficult-to-treat cancers. Biocytogen provides its off-the-shelf fully human antibody library against therapeutic targets while Moonlight Bio leads preclinical development of resulting cell therapies. Partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies to address solid tumor limitations.
- IDEAYA BiosciencesmajorOption and license agreement for IDE034, a B7H3/PTK7 bispecific TOP1 ADC. Biocytogen originally developed IDE034 and licensed to IDEAYA in July 2024. First patient dosed in Phase 1 trial February 2026 triggered $5 million milestone payment to Biocytogen. IDEAYA estimates 30-40% co-expression of both targets across major solid tumors.
- GV Safety Assessment Platform (GVSAP)standardExpanded strategic collaboration to enhance India's biopharma ecosystem by improving access to advanced biomedical research tools. Expanded alliance adds pharmacology services, gene-edited cell line licensing, and distribution to existing partnership providing Biocytogen's BioMice humanized and engineered research models to Indian researchers.
- AcepodiamajorExpanded collaboration through option-based evaluation framework for first-in-class bispecific and dual-payload ADCs (BsAD2C). Agreement enables Acepodia to evaluate and obtain exclusive worldwide license for two bispecific ADC programs. Combines Biocytogen's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation technology.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Biocytogen competitors and assessment
Company assessmentEmerging players
- Atreca: Clinical-stage biotech with an immune repertoire capture platform for antibody discovery. Comparable as an emerging antibody discovery platform company leveraging novel approaches to identify therapeutic candidates for partner pipelines.
Broad incumbents
- Regeneron Pharmaceuticals: Developer of the VelocImmune humanized mouse platform, which pioneered fully human antibody generation from transgenic mice. The original and most established competitor to Biocytogen's RenMice platforms, with a much larger commercial pipeline built on the same discovery paradigm.
- WuXi Biologics: Global leading biologics CRO/CDMO with end-to-end discovery, development, and manufacturing services. Competitor in preclinical antibody discovery and a much larger incumbent that provides similar integrated services to pharma clients, including from a China base.
Direct peers
- GenScript ProBio: Biologics CRO/CDMO division of GenScript providing antibody discovery, gene synthesis, and preclinical services. Competitor offering similar preclinical CRO and antibody discovery services to pharma/biotech clients with overlapping capabilities in humanized antibodies and gene editing.
- Adagene: AI/computation-driven antibody discovery platform developing dynamic precision medicine therapeutics. Closely comparable to Biocytogen in combining computational antibody design with proprietary platforms, and competing for similar oncology-focused pharma partners.
- Genmab: Pioneer in bispecific antibody technology with the DuoBody platform and a deep pipeline of approved/partnership antibodies. Direct peer in bispecific antibody development, which is a core capability of Biocytogen's RenLite platform.
- AbCellera Biologics: AI-powered antibody discovery platform that screens natural immune repertoires and partners with pharma on therapeutic development. Direct competitor to Biocytogen in offering fully human antibody discovery with a tech-forward platform and similar licensing + milestone + royalty revenue model.
- Harbour BioMed: Biotechnology company developing fully human antibody therapeutics using its proprietary H2L2 and HCAb transgenic mouse platforms. Closely comparable to Biocytogen in business model, technology basis, and target customer segment of pharma partners seeking humanized antibody discovery.
Others
- Twist Bioscience: Synthetic biology and DNA synthesis company offering antibody libraries and discovery tools (Twist Biopharma). Adjacent infrastructure provider rather than direct competitor, but comparable as a supplier of enabling antibody discovery technology and libraries.
Regional players
- Phanes Therapeutics: Clinical-stage biotech based in China developing bispecific and multispecific antibodies for oncology. Comparable as a regional player focused on the same bispecific antibody modality space that Biocytogen's RenLite platform addresses.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Biocytogen social profiles
Digital presenceBiocytogen compliance and trust
Trust signalCompliance2 records
Biocytogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biocytogen leadership team
Management profileNumber of profiles
Profiles3 records
Biocytogen subsidiaries and ownership
Company hierarchySubsidiaries6 records
Biocytogen funding detail
Funding detailFunding overview
Funding rounds7 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biocytogen M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biocytogen
What does Biocytogen do?
Biocytogen provides integrated antibody drug discovery solutions combining proprietary RenMice humanized mouse platforms (RenMab, RenLite, RenNano, RenTCR mimic), the AI-powered RenSuper Workstation, a 1M+ fully human antibody library, BioMice animal models, and preclinical pharmacology and gene editing services for global pharmaceutical and biotechnology clients.
Is Biocytogen a public or private company?
Biocytogen is a public company. It is classified as public and is currently operating.
When was Biocytogen founded?
Biocytogen was founded in 2008. It employs 11 to 50 people.
Where is Biocytogen based?
Biocytogen is headquartered in Daxing, China, in the Asia region.
How does Biocytogen make money?
Five revenue lines are on record. Platform Licensing is the primary driver. The others are milestone Payments, royalty on Product Sales, preclinical Services and animal Model Sales.
Who are Biocytogen's main competitors?
Atreca is listed as an emerging player. Broad incumbents are Regeneron Pharmaceuticals and WuXi Biologics. Direct peers are GenScript ProBio, Adagene, Genmab, AbCellera Biologics and Harbour BioMed. Twist Bioscience is listed as an others. Phanes Therapeutics is listed as a regional player.
Does Biocytogen have an API?
No public API is recorded for Biocytogen.
What industry is Biocytogen in?
Biocytogen's product category is Antibody Drug Discovery and Preclinical Research Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8071.